文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛消化、代谢与肾脏急症

美国退伍军人事务部医院接种疫苗成人重症COVID-19的相关因素

Factors Associated With Severe COVID-19 Among Vaccinated Adults Treated in US Veterans Affairs Hospitals.
PubMed 文献 · JAMA Netw Open · 2022-10-03
一句话结论全国性回顾性队列显示,接种后突破感染的重症风险随年龄≥50岁每增5岁aOR 1.42,免疫抑制与慢性器官病增加风险,加强针aOR 0.50降低风险。

该全国性回顾性队列纳入2020年12月15日至2022年2月28日在VA医院就诊、完成SARS-CoV-2疫苗系列后发生实验室确诊突破感染的110 760例退伍军人,其中10 612例(9.6%)为重症。重症定义为阳性检测14天内住院且血氧<94%、接受补氧或地塞米松、机械通气或28天内死亡。多因素logistic回归显示年龄是最强关联因素(≥50岁每增5岁aOR 1.42,95%CI 1.40-1.44;≥80岁相对45-50岁aOR 16.58,95%CI 13.49-20.37),免疫抑制药物、白血病/淋巴瘤、心衰、痴呆、慢性肾病亦增加风险,加强针与重症风险降低相关(aOR 0.50,95%CI 0.44-0.57)。作者认为结果可用于指导加强针外展及暴露前预防和抗病毒治疗的临床决策。

要点

  • 接种后突破感染的重症率9.6%(10 612/110 760),年龄是最强关联因素:≥50岁每增5岁aOR 1.42(95%CI 1.40-1.44)。
  • ≥80岁相对45-50岁重症aOR 16.58(95%CI 13.49-20.37),为最高危年龄段。
  • 突破感染前使用白细胞抑制剂aOR 2.80(95%CI 2.39-3.28)、细胞毒性化疗aOR 2.71(95%CI 2.27-3.24)、白血病或淋巴瘤aOR 1.87(95%CI 1.61-2.17)均与重症风险升高相关。
  • 心衰aOR 1.74(95%CI 1.61-1.88)、痴呆aOR 2.01(95%CI 1.83-2.20)、慢性肾病aOR 1.59(95%CI 1.49-1.69)与重症风险升高相关。
  • 接种额外(加强)剂量与重症风险降低相关(aOR 0.50,95%CI 0.44-0.57)。

适用人群与场景

  • 美国退伍军人中完成SARS-CoV-2疫苗系列接种、随后发生实验室确诊SARS-CoV-2感染并就诊于VA医院者,共110 760例。
  • 人群特征:97 614例(88.1%)男性,接种时平均(SD)年龄60.8(15.3)岁;26 953例(24.3%)黑人、11 259例(10.2%)西班牙裔、71 665例(64.7%)白人。
  • 数据收集时间:2020年12月15日至2022年2月28日。

诊断标准与关键阈值

  • 重症COVID-19定义:SARS-CoV-2诊断检测阳性后14天内住院,且满足以下任一:血氧水平低于94%、接受补充氧或地塞米松、机械通气、或28天内死亡。
  • 非重症为不符合上述重症定义的SARS-CoV-2感染。

研究设计与关键结果

  • 研究设计:全国性回顾性队列研究,纳入110 760例接种后突破感染患者,10 612例(9.6%)发生重症COVID-19;采用logistic回归模型估计暴露与重症的关联。
  • 年龄:≥50岁患者每增5岁重症aOR 1.42(95%CI 1.40-1.44);≥80岁相对45-50岁aOR 16.58(95%CI 13.49-20.37)。
  • 免疫抑制状态:突破感染前接受白细胞抑制剂aOR 2.80(95%CI 2.39-3.28);细胞毒性化疗aOR 2.71(95%CI 2.27-3.24);白血病或淋巴瘤aOR 1.87(95%CI 1.61-2.17)。
  • 慢性器官病:心衰aOR 1.74(95%CI 1.61-1.88);痴呆aOR 2.01(95%CI 1.83-2.20);慢性肾病aOR 1.59(95%CI 1.49-1.69)。
  • 接种额外(加强)剂量疫苗与重症风险降低相关:aOR 0.50(95%CI 0.44-0.57)。

证据类型、等级与局限

  • 证据类型:全国性回顾性队列研究(JAMA Netw Open)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,研究结果可用于指导加强针接种的外展工作。
  • 作者认为,研究结果可用于临床决策,识别最可能从暴露前预防和抗病毒治疗中获益的患者。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: With a large proportion of the US adult population vaccinated against SARS-CoV-2, it is important to identify who remains at risk of severe infection despite vaccination.

OBJECTIVE: To characterize risk factors for severe COVID-19 disease in a vaccinated population.

DESIGN, SETTING, AND PARTICIPANTS: This nationwide, retrospective cohort study included US veterans who received a SARS-CoV-2 vaccination series and later developed laboratory-confirmed SARS-CoV-2 infection and were treated at US Department of Veterans Affairs (VA) hospitals. Data were collected from December 15, 2020, through February 28, 2022.

EXPOSURES: Demographic characteristics, comorbidities, immunocompromised status, and vaccination-related variables.

MAIN OUTCOMES AND MEASURES: Development of severe vs nonsevere SARS-CoV-2 infection. Severe disease was defined as hospitalization within 14 days of a positive SARS-CoV-2 diagnostic test and either blood oxygen level of less than 94%, receipt of supplemental oxygen or dexamethasone, mechanical ventilation, or death within 28 days. Association between severe disease and exposures was estimated using logistic regression models.

RESULTS: Among 110 760 patients with infections following vaccination (97 614 [88.1%] men, mean [SD] age at vaccination, 60.8 [15.3] years; 26 953 [24.3%] Black, 11 259 [10.2%] Hispanic, and 71 665 [64.7%] White), 10 612 (9.6%) had severe COVID-19. The strongest association with risk of severe disease after vaccination was age, which increased among patients aged 50 years or older with an adjusted odds ratio (aOR) of 1.42 (CI, 1.40-1.44) per 5-year increase in age, such that patients aged 80 years or older had an aOR of 16.58 (CI, 13.49-20.37) relative to patients aged 45 to 50 years. Immunocompromising conditions, including receipt of different classes of immunosuppressive medications (eg, leukocyte inhibitor: aOR, 2.80; 95% CI, 2.39-3.28) or cytotoxic chemotherapy (aOR, 2.71; CI, 2.27-3.24) prior to breakthrough infection, or leukemias or lymphomas (aOR, 1.87; CI, 1.61-2.17) and chronic conditions associated with end-organ disease, such as heart failure (aOR, 1.74; CI, 1.61-1.88), dementia (aOR, 2.01; CI, 1.83-2.20), and chronic kidney disease (aOR, 1.59; CI, 1.49-1.69), were also associated with increased risk. Receipt of an additional (ie, booster) dose of vaccine was associated with reduced odds of severe disease (aOR, 0.50; CI, 0.44-0.57).

CONCLUSIONS AND RELEVANCE: In this nationwide, retrospective cohort of predominantly male US Veterans, we identified risk factors associated with severe disease despite vaccination. Findings could be used to inform outreach efforts for booster vaccinations and to inform clinical decision-making about patients most likely to benefit from preexposure prophylaxis and antiviral therapy.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Vo AD, La J, Wu JT, et al. Factors Associated With Severe COVID-19 Among Vaccinated Adults Treated in US Veterans Affairs Hospitals. JAMA Netw Open. 2022. PMID: 36264571. doi:10.1001/jamanetworkopen.2022.40037

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。